Showing results (101-110 of 260) with videos related to

Sort By:
Pageof 26
The Journal of Allergy and Clinical Immunology|July 4, 2016
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterizationSilvia Pesce, Marco Greppi, Giovanna Tabellini, et al.
Scientific Reports|July 2, 2024
DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killingVladimir Laletin, Pierre-Louis Bernard, Camille Montersino, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 3, 2017
The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human Vγ9Vδ2 T CellsCassie-Marie Peigné, Alexandra Léger, Marie-Claude Gesnel, et al.
Oncology Reports|January 8, 2021
Selection of tumor‑resistant variants following sustained natural killer cell‑mediated immune stressThibault Carré, Jerome Thiery, Bassam Janji, et al.
Nature Communications|December 24, 2017
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanomaFlorie Bertrand, Anne Montfort, Elie Marcheteau, et al.
Frontiers in Immunology|March 26, 2016
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsNicolas Dulphy, Anne-Sophie Chrétien, Zena Khaznadar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2009
Dok-4 is a novel negative regulator of T cell activationAudrey Gérard, Marguerite Ghiotto, Camille Fos, et al.
The Journal of Biological Chemistry|August 1, 2012
The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodiesAparna Palakodeti, Andrew Sandstrom, Lakshmi Sundaresan, et al.
Blood|January 13, 2004
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemiaMohamad Mohty, Eric Jourdan, Naira Ben Mami, et al.
Pageof 26